Labcorp Holdings stock has delivered a 52.0% return over the past three years, yet the valuation checks send mixed signals, with the Discounted Cash Flow (DCF) intrinsic value estimate suggesting the shares trade at a 44.1% discount while earnings based multiples screen as expensive.

• Over the last three years, Labcorp Holdings has returned 52.0%, which puts extra focus on whether the current price leaves enough room for further upside.
• The launch of the Marker by Labcorp Genetic Health Panel can support expectations for future cash flow, while execution risks around new consumer offerings may affect how much of that potential actually shows up in earnings.
• Labcorp Holdings scores 3 out of 6 on our valuation checks, which points to a mixed picture rather than a clear bargain or clear overvaluation 3.

The issue now is whether the DCF based intrinsic value or the richer earnings multiples provide the better guide to what Labcorp Holdings shares are really worth today.

Does Labcorp Holdings Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model values Labcorp Holdings by projecting future cash the business can return to shareholders and then discounting it back to today. On this view, Labcorp generated about $1.3b of free cash flow over the latest twelve months, with the model assuming that cash flows grow from this base rather than shrinking. That stream of cash flows, run through a 2 Stage Free Cash Flow to Equity framework, points to an estimated intrinsic value of about $565 per share.

Compared with the current share price, that DCF estimate suggests Labcorp Holdings trades at roughly a 44.1% discount, which screens as materially undervalued on a cash flow basis. The recent launch of the Marker by Labcorp Genetic Health Panel helps explain why the cash flow outlook in the model incorporates ongoing growth potential, even though actual earnings will depend on how well the new offering gains traction with consumers.

On these cash flow assumptions, Labcorp Holdings stock appears undervalued relative to its DCF based intrinsic value.

Our Discounted Cash Flow (DCF) analysis suggests Labcorp Holdings is undervalued by 44.1%. Track this in your watchlist or portfolio, or discover 56 more high quality undervalued stocks.

Has Labcorp Holdings Run Too Far on Earnings?

P/E is usually a clean way to check what you are paying for each dollar of Labcorp Holdings earnings. On this measure, the stock currently trades on a P/E of 27.5x. That sits slightly above the wider Healthcare industry average of about 25.7x and below the peer group average of about 39.8x, so the stock is not the most expensive in its space but it is not priced at a clear discount either.

The fair P/E ratio for Labcorp Holdings, based on its profile and risk factors, is estimated at about 24.2x. Compared with the current 27.5x multiple, that points to a premium of a few turns of earnings, which indicates that investors are already paying up for the current earnings base. For anyone weighing the DCF upside against this richer earnings multiple, it is worth noting that the market is not treating Labcorp as a bargain on P/E terms right now.

On the P/E multiple alone, Labcorp Holdings stock appears overvalued relative to what the model flags as a fair earnings-based ratio.

The Labcorp Holdings Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Labcorp Holdings pick up where this valuation puzzle leaves off. They set out the specific growth, margin and earnings paths that would need to play out for Labcorp Holdings' stock to be worth meaningfully more or less than today, and they sit on the company’s Community page. Where a single ratio or model gives one figure, these narratives outline the future that figure relies on so you can monitor whether it stays on track.

Share a narrative on Labcorp Holdings' stock to provide a clear, number driven view on whether the Marker by Labcorp Genetic Health Panel delivers for shareholders and track how that thesis holds up as new results arrive.

Do you think there's more to the story for Labcorp Holdings? Head over to our Community to see what others are saying!

The Bottom Line

Labcorp Holdings sits in a genuine valuation tug of war. The Discounted Cash Flow (DCF) intrinsic value estimate points to the stock trading at a sizeable discount, while the P/E multiple screens as overvalued relative to the earnings based fair ratio. That split reflects a market that already prices in healthier growth and sentiment than the broader valuation checks fully support. The crux from here is whether Labcorp converts the Marker by Labcorp Genetic Health Panel and other initiatives into durable cash flows without eroding returns, or whether the current earnings multiple proves too full for the execution risk involved.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.